This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Regeneron Announces First Recipients Of Annual "Regeneron Prize For Creative Innovation"

TARRYTOWN, N.Y., June 27, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first recipients of the Regeneron Prize for Creative Innovation, a new initiative designed to acknowledge, reward, and foster talented early-career scientists.   

"We are excited to offer the Regeneron Prize for Creative Innovation to scientists who are beginning their research careers and show great promise," said George Yancopoulos, M.D., Ph.D., Founding Scientist, President, Regeneron Laboratories, and Chief Scientific Officer, who designed the program as a way to identify and track developing scientific talent.  "We believe this program demonstrates the Company's commitment to supporting science education and research excellence."

Regeneron is awarding two prizes for outstanding research this year. 

  • The Regeneron Prize for Creative Innovation by a Postdoctoral Fellow has been awarded to Chuan Wu, Brigham and Women's Hospital, Harvard University.
  • The Regeneron Prize for Creative Innovation by a Graduate Student has been awarded to Cody Gilleland, Massachusetts Institute of Technology.

Additionally, this year Regeneron is recognizing two graduate student researchers with Honorable Mentions: Daria Zamolodchikov, Rockefeller University and Lukasz Bugaj, University of California at Berkeley. 

Requests for applicants were distributed to key academic institutions around the nation in February.  Each institution was asked to nominate two graduate students and two postdoctoral fellows.

A key component of each application was a proposal, drafted by the nominee, explaining a "dream" project in biomedical research.  This proposal gave the review committee at Regeneron insights into the nominee's creativity and ability to think independently as a scientist.  Each nominee also included a curriculum vitae and list of publications; the trainee's productivity in his or her current laboratory also factored into the review committee's decision.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs